Rubicon Research Ltd
Rubicon Research Ltd is a biotechnology company focused on healthcare diagnostics, generating revenue primarily through the development and commercialization of diagnostic products and services.
Business. Rubicon Research Ltd (RUBI.NS) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Rubicon Research Ltd (RUBI.NS) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.
Rubicon Research Ltd maintains a debt-to-equity ratio of 0.77, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is characterized as medium, with a current ratio of 1.35, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not in excess. The company's cash and equivalents amount to INR 1,162.09 million, while its long-term debt stands at INR 4,176.11 million, resulting in a net cash position that is negative after subtracting total debt.
In terms of profitability, Rubicon Research Ltd demonstrates a return on equity (ROE) of 24.84% and a return on assets (ROA) of 9.26%, both of which are strong indicators of efficient use of equity and assets to generate profit. The company's operating income of INR 2,193.58 million and net income of INR 1,343.61 million reflect a healthy margin structure, which is in line with the industry's preferred metrics for profitability.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risk if the segment or region experiences a downturn.
Looking ahead, Rubicon Research Ltd is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. The company's capital expenditure of INR -702.24 million indicates a reduction in investment in physical assets, which may be a strategic decision to preserve cash or a sign of a mature business with fewer expansion opportunities.
The risk assessment for Rubicon Research Ltd highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations without additional financing. However, the low dilution risk suggests that the company is not expected to issue a significant number of new shares in the near term, preserving the value of existing shareholders' equity.
Recent events and filings do not indicate any material changes in the company's operations or financial strategy. The company's strong buy recommendation from analysts, with a mean price target of INR 910.00, suggests a positive outlook from the investment community.
- Rubicon Research Ltd has a strong return on equity (24.84%) and a healthy return on assets (9.26%), indicating efficient use of capital.
- The company's liquidity position is moderate, with a current ratio of 1.35 and a net cash position that is negative after subtracting total debt.
- The company's revenue is concentrated in a single business segment, which may increase its exposure to market-specific risks.
- Analysts have a positive outlook on the company, with a mean price target of INR 910.00 and a strong buy recommendation.
- The company is not expected to issue a significant number of new shares in the near term, preserving the value of existing shareholders' equity.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Rubicon Research Ltd Market data — financials · 2026-05-29
- Rubicon Research Ltd Market data — analyst estimates · 2026-05-29
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 11.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 34.2%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.70xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.93xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 241.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -89.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -89.2%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 8.6%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 7.9%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -0.2%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): -2.8%Derived (calculated)
- Revenue (annual): USD 23.52MSEC XBRL filing
- Total assets (annual): USD 134.07MSEC XBRL filing
- Shareholders' equity (annual): USD 45.8MSEC XBRL filing
- Operating income (annual): USD 12.4MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 49SEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 49SEC XBRL filing
- Operating cash flow (annual): USD 11.33MSEC XBRL filing
- Long-term debt (annual): USD 82.28MSEC XBRL filing
- Shares outstanding (annual): 385.5KSEC XBRL filing
- Cash & equivalents (annual): USD 3.96MSEC XBRL filing
- Current assets (annual): USD 7.05MSEC XBRL filing
- Current liabilities (annual): USD 10MSEC XBRL filing